Skip to main content
Clinical Trials/CTRI/2025/09/094869
CTRI/2025/09/094869Not yet recruitingNot Applicable

Comparison of Two Different Doses of Sugammadex for Reversal of Rocuronium Induced Neuromuscular Blockade

Dr Annie Paul1 site in 1 country66 target enrollmentStarted: October 1, 2025Last updated:

Trial Snapshot

Phase
Not Applicable
Status
Not yet recruiting
Sponsor
Enrollment
66
Locations
1
Primary Endpoint
Time from administration of Sugammadex to achieving TOFR greater than 0.9

Study Overview

Brief Summary

This study compares the efficacy of two doses of Sugammadex, 1mg per kg and 2mg per kg, a drug used to reverse Rocuronium induced neuromuscular blockade in surgical patients. Outcomes include time to full reversal, percentage achieving target within 5min.

Study Design

Study Type
Interventional
Allocation
Randomized
Masking
None

Eligibility Criteria

Ages
18.00 Year(s) to 65.00 Year(s) (—)
Sex
All

Inclusion Criteria

  • ASA physical status 1 or 2 Surgeries under general anaesthesia with controlled ventilation for equal or greater than 40 minutes duration.

Exclusion Criteria

  • Known hypersensitivity to study drugs Neuromuscular disorders Medications altering effects of NMBA.

Outcomes

Primary Outcomes

Time from administration of Sugammadex to achieving TOFR greater than 0.9

Time Frame: 18 months

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Dr Annie Paul
Sponsor Class
Government medical college
Responsible Party
Principal Investigator
Principal Investigator

Dr Annie Paul

Vardhman Mahavir Medical College and Safdarjung Hospital

Study Sites (1)

Loading locations...

Similar Trials

Comparing Two Doses of Sugammadex for... | Clinical Trial